Colorectal Cancer: Immune Evasion REVERSED!

14 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Uncover a revolutionary peptide discovery poised to transform colorectal cancer research by fundamentally reprogramming immune evasion mechanisms, especially in challenging 'cold' tumors. Sonia Rao from Peptides.today dives deep into an 11-amino acid peptide derived from the APC protein. This novel peptide precisely targets and inhibits PTPN13, a pivotal orchestrator of immune suppression within the tumor microenvironment. By reactivating T-cell signaling, it effectively converts immunosuppressive, 'cold' tumors into reactive ones, significantly enhancing the efficacy of immune checkpoint blockade in experimental models. Learn about its broad-spectrum activity across various CRC subtypes, the intricate biochemical and structural insights, and the potential to address a critical research gap. We also explore the extensive journey from preclinical discovery through the regulatory hurdles of IND application and the multi-year phases of clinical research (Phase 1, 2, 3), providing a realistic timeline for its research validation. Stay ahead of the curve with this game-changing insight into immune modulation strategies for colorectal cancer. Follow Sonia Rao and Peptides.today for cutting-edge peptide pipeline insights. This video is for informational purposes only and is not medical advice. All compounds discussed are for research use only and not for human consumption. Always consult a licensed healthcare provider for medical needs. #ColorectalCancer #CRCresearch #PeptideTherapy #ImmunoOncology #CancerResearch
Categoria
Oncology
Commenta per primo questo video.

Prossimo